Characteristics of exceptional responders to lenalidomidebased therapy in multiple myeloma

Blood Cancer Journal

Volumn 5, Issue 10, 2015, Pages

  Vu, T ^a   Gonsalves, W ^b   Kumar, S ^b   Dispenzieri, A ^b   Lacy, M Q ^b   Buadi, F ^b   Gertz, M A ^b   Rajkumar, S V ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; ARTICLE; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOGENETICS; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT RESPONSE; TRISOMY; ANALOGS AND DERIVATIVES; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84989904793     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.91     Document Type: Article

References (26)

1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538-e548.
2. Russell SJ, Rajkumar SV. Multiple myeloma and the road to personalised medicine. Lancet Oncol 2011; 12: 617-619.
3. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc 2013; 88: 360-376.
4. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119: 2100-2105.
5. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015; 125: 2068-2074.
6. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
7. Greipp PR, San Miguel JF, Durie BG, Avet-Loiseau H, Fonseca R, Jacobson JL et al. A New International Staging System (ISS) for Multiple Myeloma (MM) from the International Myeloma Working Group. Blood 2003; 102: A664.
8. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015; 33: 2863-2869.
9. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009; 114: 3139-3146.
10. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612-2624.
11. Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan- prednisone. Blood 2010; 116: 3743-3750.
12. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011; 117: 3025-3031.
13. Printz C. NCI launches exceptional responders initiative: researchers will attempt to identify why some patients respond to treatment so much better than others. Cancer 2015; 121: 803-804.
14. Sheridan C. Cancer centers zero in on exceptional responders. Nat Biotechnol 2014; 32: 703-704.
15. Poh A. In search of exceptional responders. Cancer Discov 2015; 5: 8.
16. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
17. Dimopoulos MA, Swern AS, Li JS, Hussein M, Weiss L, Nagarwala Y et al. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J 2014; 4: e257.
18. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417-1424.
19. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities in multiple myeloma: an Eastern Cooperative Oncology Group Study. Cancer Res 2002; 62: 715-720.
20. Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 2014; 28: 398-403.
21. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014; 371: 906-917.
22. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1, 027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc 2003; 78: 21-33.
23. Pandey S, Rajkumar SV, Kapoor P, Ketterling RP, Lacy MQ, Gertz MA et al. Impact of FISH abnormalities on response to lenalidomide in patients with multiple myeloma. ASH Annu Meeting Abstr 2013; 122: 3210.
24. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013; 121: 884-892.
25. Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013; 27: 1738-1744.
26. Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J 2013; 3: e148.